AUTH/1794/2/06: Men’s health physician/GP v Ipsen (Decapeptyl) – no breach over “advanced” prostate cancer wording | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/1794/2/06
Parties	Men’s Health Physician/General Practitioner v Ipsen Ltd
Product	Decapeptyl (triptorelin)
Issue	Alleged misleading statement about licensed indication (interpretation of “advanced prostate cancer”)
Setting	Educational meeting / exhibition stand at Institute of Physics (Ipsen: December 2005 conference)
Complaint received	02 February 2006
Case completed	10 March 2006
Applicable Code year	2003
Clauses considered	3.2, 7.2, 15.2
Decision	No breach
Appeal	No appeal

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A men’s health physician/GP complained about what an Ipsen representative said at a UK prostate cancer educational meeting (Ipsen said it was the 3rd National Conference on Prostate Cancer: Meeting the Challenge, December 2005, Institute of Physics).
The doctor alleged the representative said Decapeptyl (triptorelin) could be used when prostate cancer had “spread beyond the gland”, which the complainant interpreted as including both locally advanced and advanced disease.
The complainant’s view: “advanced” prostate cancer meant metastatic (M1) disease under TNM criteria; “locally advanced” was non-metastatic but beyond the prostatic capsule (with/without regional lymph node involvement).
Ipsen’s position: the term “advanced prostate cancer” is not clinically precise; it can reasonably include disease beyond the prostatic capsule (including locally advanced and metastatic). Ipsen provided clinical trial population details supporting a broader mix than metastatic-only.
The representatives could not recall the specific conversation; the complainant’s identity was not revealed to Ipsen.

⚖️

⌄

No breach of the Code was ruled.
The Panel considered it could not determine exactly what happened, but on the information available did not consider Decapeptyl had been promoted beyond its licensed indication or that the complainant had been misled.
No appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access